Compare Meta Platforms Inc (META) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs Pfizer Inc — how do they compare? Meta Platforms Inc trades at $724.07 (market cap $1.84T), while Pfizer Inc trades at $27.83 (market cap $158.56B). The key difference: Meta Platforms Inc is far larger — about 11.6× Pfizer Inc's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Meta Platforms Inc for 127 Days and Pfizer Inc for 158 Days on average.
| META | PFE | |
|---|---|---|
Market Cap | $1.84T | $158.56B |
Volume | 12,743,601 | 44,138,282 |
Sector | Media | Health |
52-Week High | $777.59 | $29.02 |
52-Week Low | $525.72 | $23.67 |
Typical Hold Time | 127 Days | 158 Days |
Enterprise Value | $1.86T | $210.06B |
Dividend Yield | 0.29% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Meta Platforms (META) trades at $721.31, down 2.38% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish trend in moving averages but neutral oscillators, with key support at $719 and resistance at $726. Fundamentally, revenue grew to $200.97B in 2025 with a net income margin of 29.84%, though Q2 2026 EPS missed expectations. Recent news highlights the launch of the Muse Spark AI model and a legal ruling on a youth addiction lawsuit in Massachusetts.
The outlook for META remains positive with strong analyst support—80% recommend Buy and a consensus price target of $781.00—driven by AI innovation and revenue growth. However, risks include regulatory challenges and high capital expenditures. Investors should weigh robust profitability against legal and competitive pressures in the social media and AI sectors.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
